Home » Newsletters » BioWorld Science

BioWorld Science

July 11, 2001

View Archived Issues

SPP-301 enters phase I evaluation

Kucera focuses on prodrug carriers for various diseases

Company Profile: Prana Biotechnology

Servier characterizes mixed TP/5-HT2A receptor antagonist at ISTH meeting

Novel anticoagulant targets surface-bound thrombin, may be preferable to heparin

Orally active gpIIb/IIIa antagonist shows broad-spectrum antiplatelet effects

Antithrombin and antithrombotic effects of LB-30057 discussed at ISTH meeting

ISTH news: antiplatelet/anticoagulant effects of PI-88 characterized

Ivax boosts immunotoxin program with new agreement

CS-747 emerges as a useful antiplatelet agent for thrombotic disorders

Pharmexa begins phase I/II trial of therapeutic vaccine for breast cancer in Denmark

FDA requests further data on Xolair, delaying approval

NeoGenesis and Biogen expand small-molecule research alliance

Committee concludes positive interim safety review of tgAAVCF trial

Synthetic heparin mimetic exerts potent antithrombotic activity with less hemostatic impairment

Ad-vIL-10 as a promising strategy for human uveitis

Aventis transfers selected product rights to Introgen Therapeutics through investment

WHI-P131 useful for preventing colorectal cancer

Antithrombotics for both intravenous and oral administration patented by Fournier

Japanese lab prepares anti-HIV thiamine disulfides with improved water solubility

Kissei presents new series of D2 antagonists/5-HT4 agonists

Potent antiarthritic compounds from Dainippon with excellent safety

Inhibitors of sPLA2 and their use reported by Shionogi team

Adolor's ADL-8-2698 enters phase III for second indication

S-Allylmercaptoglutathine useful for atherosclerosis, lipid and weight disorders, cancer, etc.

SCRAS patents new series of inhibitors of NOS and/or MAO

Promising phase III trial results reported with Leuprogel three-month depot

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...